Concomitant coronary and peripheral artery disease is associated with higher periprocedural and long-term percutaneous coronary intervention (PCI) complication rates. We evaluated in-hospital and 1-year clinical outcomes of patients with low or borderline ankle-brachial indexes (ABIs) undergoing PCIs in the drug-eluting stent era. We divided 1370 SHINANO registry patients into 3 groups-low (ABI 0.9), borderline (0.9 < ABI 1.0), and normal (1.0 ABI < 1.4). During the 1-year followup, more PCI-related complications occurred in the low and borderline ABI groups than in the normal ABI group (7.7% vs 8.8% vs 4.0%, respectively). Low ABI patients were more likely to experience adverse clinical events (6.3% vs 3.6% vs 3.0%, respectively; log-rank P ¼ .020 for low vs normal ABI), with a hazard ratio of 2.27 (95% confidence interval, 1.12-4.61; P ¼ .023), compared with patients with normal ABIs. Patients with abnormal ABIs had a significantly higher incidence of PCI-related complications and a less favorable 1-year prognosis. Routine ABI measurement before PCI may help predict PCI-related complication incidence and 1-year prognosis.
Introduction
Atherosclerosis is a systemic disease that affects coronary, cerebral, and lower-extremity arteries and is associated with the primary worldwide cause of mortality. 1 Patients with peripheral artery disease (PAD) have a poor long-term prognosis, regardless of whether they are symptomatic. 2 Although the prevalence of asymptomatic PAD is high in patients with cardiovascular (CV) risk factors, a considerable number of patients with PAD remain undiagnosed. 3 The ankle-brachial index (ABI) has become the gold standard for PAD detection, because of its simplicity, reproducibility, and cost-effectiveness. 4 The ABI measurements 0.90 and 0.90 to 0.99 can identify patients with definite and borderline PAD, respectively. Patients with even borderline PAD may be at increased risk of subsequent CV events. 5, 6 Thus, ABI measurement may help to identify asymptomatic individuals with CV risk. 7 Patients with coronary artery disease (CAD) generally receive percutaneous coronary intervention (PCI). In recent years, PCI has become safer and less invasive owing to the development of devices and approaches, such as the transradial approach and slender PCI. 8, 9 Although drug-eluting stents (DESs) markedly reduce the rates of target lesion revascularization, 10 the safety of discontinuing dual antiplatelet therapy remains controversial in terms of late or very late stent thrombosis even after the advent of second-generation DES. 11 In fact, more than half of the patients with PAD have concomitant CAD. 12, 13 Patients with concomitant CAD and PAD who underwent PCI had higher periprocedural and long-term complications than those without PAD in the era of the bare metal stent 14, 15 ; however, the clinical outcomes of patients with definite or borderline PAD have not been systematically studied in the era of the DES. Therefore, we evaluated the in-hospital and 1-year clinical outcomes of patients with definite or borderline PAD who underwent PCI in the DES era.
Materials and Methods

Study Population
The study protocol was developed in accordance with the Declaration of Helsinki and was approved by the ethics committee of each participating institution. All patients gave written informed consent before participating in this study. This retrospective cohort study used data obtained from the Shinshu Prospective Multicenter Analysis for Elderly Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention (SHINANO) registry, the details of which have been published previously. 16 Briefly, the SHINANO registry is a prospective, multicenter, observational registry designed to compare differences in baseline characteristics and short-term and long-term outcomes after initial PCI between elderly and nonelderly patients. Between August 2012 and July 2013, a total of 1923 consecutive patients with all forms of CAD (stable angina, ST-segment elevation myocardial infarction, non-ST-segment elevation myocardial infarction, and unstable angina) were enrolled from 16 institutions located in the Nagano Prefecture of Japan. This registry applied no exclusion criteria. It was registered with the University Hospital Medical Information Network Clinical Trials Registry, which is accepted by the International Committee of Medical Journal Editors (No. UMIN000010070).
For the current subanalysis, we identified 1370 patients in whom ABIs were measured and divided them into 3 groups according to the 2011 American College of Cardiology Foundation/American Heart Association (AHA) guideline classification 17 -low ABI (n ¼ 209; ABI 0.9), borderline ABI (n ¼ 171; 0.9 < ABI 1.0), and normal ABI (n ¼ 990; 1.0 ABI < 1.4). Patients with values indicating noncompressible arteries (ie, ABI > 1.4) in either limb were excluded. The ABI was measured with patients in the supine position after at least 5 minutes of rest using an automatic oscillometric apparatus according to the recommendations of the AHA. 18 The ABI was calculated separately for each leg, and the lower of the 2 values was used for analysis. Patients were prospectively followed up for 1 year (Figure 1) .
The in-hospital end point was the incidence of PCI-related complications, including periprocedural myocardial infarction, periprocedural stroke, coronary perforation, bleeding complications, contrast-induced nephropathy, and cholesterol crystal embolization. The 1-year end point was net adverse clinical events (NACEs), defined as the combined incidence of CV death, nonfatal myocardial infarction, ischemic or hemorrhagic strokes, and major bleeding at 1 year after hospital discharge. 
Definitions
Periprocedural myocardial infarction was defined as a creatine kinase or creatine kinase-MB fraction above the upper limit of normal at each hospital or as the development of significant Q waves in at least 2 contiguous electrocardiogram leads. Periprocedural stroke was defined as a nonhemorrhagic stroke or transient ischemic attack related to PCI in the absence of other causes. A consultant neurologist evaluated all patients experiencing ischemic strokes after PCI. 19 Bleeding complications were defined as blood transfusions or prolonged hospitalization owing to hematoma, gastrointestinal bleeding, or intracranial bleeding. Contrast-induced nephropathy was defined as an increase in the serum creatinine level of 25% or an increase of 0.5 mg/dL from baseline within 72 hours of contrast exposure. The CV death was defined as any death due to an immediate cardiac or vascular cause, such as fatal myocardial infarction, ischemic or hemorrhagic stroke, aortic dissection, aneurysm rupture, gastrointestinal hemorrhage, or unexpected sudden death. Documented PAD consisted of 1 or both of the following criteria-current intermittent claudication with an ABI 0.9 or a history of intermittent claudication with a previous related intervention.
Statistical Analysis
Continuous variables are presented as mean (standard deviation), and binary variables are described as numbers and percentages. Differences between ABI groups were compared using the Kruskal-Wallis test for continuous variables and the Pearson w 2 test for categorical variables. The landmark analysis was performed in accordance with a landmark point at hospital discharge, with the hazard ratio calculated for events that occurred between discharge and the end of the follow-up period. The Kaplan-Meier test was performed to assess the cumulative incidence of NACE, and the logrank test was used to compare survival curves. A multivariate Cox regression analysis was performed to determine the independent predictors of NACE in the study population. A 2-tailed P < .05 was considered significant. Statistical analysis was performed using the Statistical Package for Social Sciences version 21 for Windows (SPSS Inc, Chicago, Illinois).
Results
Baseline Demographics and Lesion Characteristics
Patient and lesion characteristics are shown in Tables 1 and 2 , respectively. The prevalence of low, borderline, and normal ABI values was 15.3% (n ¼ 209), 12.5% (n ¼ 171), and 72.3% (n ¼ 990), respectively. In the low ABI group, 57.7% of patients were diagnosed with PAD before receiving PCI.
The ABI values decreased with older age and increasing leanness in patients. There were significantly more female patients in the low and borderline ABI groups, and they had more comorbid conditions, including diabetes, atrial fibrillation, and renal dysfunction. Only anticoagulants, statins, and insulin use were significantly different between groups at discharge, which could reflect patient characteristics. Compared with patients with normal ABIs, patients with low and borderline ABIs had more complex lesions, including multivessel disease, diffuse lesions, left main trunk disease, ostial lesions, and calcified lesions requiring rotational atherectomy. The SYNTAX score was significantly higher, and the rate of using a transradial approach was significantly lower in these patients, reflecting lesion complexity. Although the rate of DES use was comparable across the groups, the rate of continued dual antiplatelet therapy tended to be higher in the low and borderline ABI groups than in the normal ABI group. Figure 2 shows the incidence of PCI-related complications during hospitalization. Compared with patients with normal ABIs, patients with low and borderline ABIs tended to experience more frequent periprocedural strokes (1.0% vs 1.8% vs 0.3% for low ABI, borderline ABI, and normal ABI groups, respectively; P ¼ .183 for low ABI, P ¼ .014 for borderline ABI, vs normal ABI, respectively) and contrast-induced nephropathy (1.9% vs 2.9% vs 0.8%, respectively; P ¼ .145, P ¼ .015, vs normal ABI, respectively). There were no significant differences between groups in terms of the rates of periprocedural myocardial infarction (2.4% vs 2.9% vs 1.5%, respectively; P ¼ .368, P ¼ .191, vs normal ABI, respectively) or bleeding complications (1.9% vs 1.2% vs 1.1%, respectively; P ¼ .343, P ¼ .945, vs normal ABI, respectively). Overall, patients with low and borderline ABIs had a significantly higher incidence of PCI-related complications than did patients with normal ABIs (7.7% vs 8.8% vs 4.0%, respectively; P ¼ .024, P ¼ .017, vs normal ABI, respectively). In addition, multiple logistic regression analysis revealed that low and borderline ABIs were independent predictors of PCI-related complications, even after adjustment for conventional confounding factors, including age, sex, hypertension, current smoking, dyslipidemia, and diabetes (odds ratio [ Clinical Outcomes During the 1-Year Follow-Up Figure 3 shows the Kaplan-Meier analysis for 1-year follow-up, and Table 3 presents the Cox proportional hazard regression analysis for NACE. Patients with low ABI had a significantly higher incidence of NACE (6.3% vs 3.6% vs 3.0%, for low ABI, borderline ABI, and normal ABI, respectively; logrank P ¼ .020 for low vs normal ABI). After adjustment for conventional confounding factors, including age (quartiles), sex, current smoking, hypertension, dyslipidemia, and diabetes, low ABI remained an independent predictor of NACE (hazard risk [HR]: 2.27, 95% CI: 1.12-4.61, P ¼ .023), CV death (HR: 4.94, 95% CI: 1.19-20.58, P ¼ .028), stroke (HR: 4.42, 95% CI: 1.14-17.15, P ¼ .032), and major bleeding (HR: 3.89, 95% CI: 1.28-11.82, P ¼ .017). Although patients with borderline ABI had an incidence of NACE comparable to that in controls (HR: 1.10, 95% CI: 0.45-2.68, P ¼ .838), they tended to experience CV death (HR: 3.51, 95% CI: 0.82-15.08, P ¼ .091) and major bleeding (HR: 3.21, 95% CI: 1.05-9.79, P ¼ .041) more frequently. Interestingly, hemorrhagic events occurred more frequently in the low and borderline groups. In the breakdown of all CV death events, the proportion of hemorrhage-related CV death in low and borderline ABI groups was significantly higher than that in the normal ABI group (50% vs 67% vs 20%, for low ABI, borderline ABI, and normal ABI, respectively; P ¼ .011 for low ABI, P ¼ .024 for borderline ABI, vs normal ABI, respectively; Figure 4A ). Additionally, in the breakdown of all stroke events, intracerebral bleeding was involved in 40% in the low ABI group and 50% in the borderline ABI group, while all strokes in the normal ABI group were ischemic strokes (P ¼ .002 for low ABI, P ¼ .156 for borderline ABI, vs normal ABI, respectively; Figure 4B ).
Percutaneous Coronary Intervention-Related Complications
Discussion
The present results clearly demonstrate that low ABI was significantly associated with increased risk of PCI-related complications and 1-year CV events. In addition, a borderline ABI was associated with a higher risk of PCI-related complications; this relationship remained significant even after adjusting for potential confounding factors. Furthermore, hemorrhage-related CV death and intracerebral bleeding during the 1-year follow-up were more frequently reported in the low and borderline ABI groups.
In a previous report from the bare metal stent era, Saw et al presented a pooled analysis of 19 867 patients undergoing PCI.
14 Patients with PAD had a higher incidence of 7-day death (1.0% vs 0.4%; P < .001), 7-day myocardial infarction (6.8% vs 5.6%; P ¼ .047), and 1-year death (5.0% vs 2.1%; P < .001) than patients without PAD. Singh et al analyzed the outcomes of 7696 patients undergoing PCI and reported that patients with PAD had a higher incidence of in-hospital complications than did patients without PAD, including death (3% vs 1%, respectively; P < .001), myocardial infarction (8% vs 5%, respectively; P < .001), and blood loss requiring transfusion (11% vs 6%, respectively; P < .001). 15 Compared with previous reports, the current study showed that PCI is now safer than before, in terms of periprocedural myocardial infarction and major bleeding; however, the risk of PCI-related complications and less favorable 1-year prognoses remain higher in patients with PAD, despite recent developments in devices and techniques.
The ABI is an easy and reliable tool for identifying patients with subclinical PAD and indicating generalized atherosclerosis. 7, 18 An ABI 0.90 is significantly associated with an increased risk of all-cause and CV mortality. [20] [21] [22] [23] Carvounis and Nikas have reported that 28% of patients with CV risks had asymptomatic PAD, defined as an ABI 0.90. 3 In the present study, the patients' mean age was 70.4 + 11.0 years, which is higher than that reported by Carvounis and Nikas, and more than 40% of patients with low ABIs were not diagnosed with PAD before the PCI procedure. Routine ABI measurement may improve the prediction of PCI-related complications and 1-year prognosis.
Percutaneous Coronary Intervention-Related Complications
In the present study, patients with low and borderline ABIs had significantly higher SYNTAX scores and experienced PCIrelated complications more frequently than did patients with normal ABIs. Additionally, lesion complexity itself seemed to affect the incidence of PCI-related complications. Previously, Sebastianski et al reported that patients with PAD were more likely to have high SYNTAX scores, 24 and Endo et al reported that angiographic lesion complexity was associated with inhospital mortality and complication rate. 25 In our study, patients with low ABIs tended to experience more frequent bleeding complications, although this result was not statistically significant. Fewer patients with abnormal ABIs underwent PCI via a transradial approach. In addition, PCI operators may need to conduct PCIs through the transbrachial approach in patients with low ABIs, due to atherosclerotic lesions in the iliac artery or the necessity to avoid radial punctures in anticipation of future hemodialysis access; this approach could increase vascular access site complications. Furthermore, complex lesions frequently require thicker guiding catheters, and the use of 7F and 8F guides to perform PCI was associated with increased contrast volume, renal complications, bleeding, and vascular access site complications when compared to 6F guides. 26 Although the total incidence of periprocedural myocardial infarction in this study (1.8%) was less than that reported in previous reviews, 27 patients with low and borderline ABIs tended to experience this complication more frequently than patients with normal ABIs, although the difference was not statistically significant. An intravascular ultrasound study has shown a strong correlation between the atherosclerotic plaque burden and the incidence of periprocedural myocardial infarctions. 28 Patients with multivessel disease, multiple or long lesions, or diffusely diseased arteries have a larger atherosclerotic burden and are more prone to periprocedural myocardial infarction. Complex lesions requiring complex PCIs predispose patients to periprocedural myocardial infarction. 29 Periprocedural stroke is a rare, but serious, complication of PCI. The overall rate of periprocedural stroke in this study (0.5%) is comparable to that in previous reports. 30 Percutaneous coronary intervention is an invasive procedure in which catheter manipulation mechanically stresses the arterial vascular system; this is likely the major cause for cerebral embolism during cardiac catheterization. 31, 32 Patients with low and borderline ABIs might be in the progressive stage of atherosclerosis, and therefore, they tend to experience periprocedural stroke more frequently than patients with normal ABIs.
One-Year Prognosis
It is important to note that patients with a low ABI had a significantly higher incidence of NACE during the 1-year follow-up after hospital discharge. These patients had hemorrhagic events, in particular. Patients with borderline ABIs also tended to experience CV death and major bleeding more frequently. In contrast, there was no significant difference in nonhemorrhage-related events between the 3 groups.
Compared with the normal ABI group, patients with low and borderline ABIs had more frequent hemorrhagic CV and stroke events. Patients with PAD are at higher risk of major hemorrhagic events than are patients with CAD. 33 Recently, Lee et al reported that borderline ABI was associated with a higher stroke rate (including brain hemorrhage) in patients who underwent PCI than was normal ABI. 34 Although DES use did not vary significantly between groups, the rate of continuing dual antiplatelet therapy tended to be higher in the low and borderline ABI groups. Stenting of complex lesions, such as those involving the left main trunk, calcified lesions related to incomplete stent apposition, and diffuse lesions may compel physicians to continue dual antiplatelet therapy. 11 These patients have significantly higher rates of atrial fibrillation and receive more anticoagulant therapy, both of which could lead to more frequent hemorrhagic events. 35 On one hand, patients with low or borderline ABI were significantly older in this study; thus, it remains possible that more patients with atrial fibrillation who received anticoagulants were inadvertently categorized in the low or borderline ABI group in this study, and as a result, they had more hemorrhagic events. Nevertheless, in patients with PAD, the combination of oral anticoagulant and antiplatelet therapy has been associated with an increase in life-threatening bleeding. 36 Spontaneous bleeding after PCI was independently associated with a higher long-term mortality and conveyed a risk comparable to that of myocardial infarction. 37 These findings suggest the importance of personalized antithrombotic therapy after PCI, based on each patient's risk of thrombotic and hemorrhagic events.
This study has limitations. The decision to perform PCI was at the operator's discretion; thus, selection bias could be present. There were significant differences in the rates of acute coronary syndrome across the groups, and 2% of patients who died owing to acute coronary syndrome before ABI measurement were excluded, which could have affected the in-hospital results. Accordingly, we established PCI-related complications instead of in-hospital mortality as the in-hospital end point. Moreover, we chose hospital discharge as a landmark point to reduce the influence of primary disease and PCI-related complications on 1-year prognosis.
Conclusion
Patients with low and borderline ABIs had a significantly higher incidence of PCI-related complications and a less favorable 1-year prognosis than patients with normal ABIs, particularly in terms of major bleeding events; PCI operators should carefully monitor these patients. Routine ABI measurement before PCI may allow PCI operators to predict the risk of PCI-related complications and the 1-year prognosis after hospital discharge.
